8-K: Firefly Neuroscience Secures $1.2 Million in Private Placement Offering

Firefly Neuroscience, Inc. has completed a private placement, raising $1.2 million through the issuance of units comprising common stock or pre-funded warrants, alongside two types of common stock purchase warrants.

Summary

• Firefly Neuroscience, Inc. (AIFF) entered into a Securities Purchase Agreement on June 16, 2025, with certain accredited investors.
• The company issued and sold 400,000 units at a purchase price of $3.00 per unit, resulting in gross proceeds of $1,200,000.
• Each unit consists of either one share of common stock or a pre-funded warrant to purchase one share (at a nominal exercise price of $0.0001), plus one common stock purchase warrant exercisable at $3.50 per share and another exercisable at $4.00 per share.
• Both common stock purchase warrants have a five-year term from their initial exercise date.
• The securities were offered and sold as a private placement, relying on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b) of Regulation D.
• The net proceeds from the offering are designated for general corporate and working capital purposes, as well as to cover fees and expenses associated with the issuance.
• Key investors in this transaction include Roxy Capital Corp, which purchased 250,000 units for $750,000, and RJL18 Capital GP LLC, which purchased 150,000 units for $450,000.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for general corporate and working capital purposes, which is a positive for the company's operational stability. However, the issuance of warrants introduces potential future dilution for existing shareholders. The terms appear standard for a private placement of this nature, without exceptionally favorable or unfavorable conditions that would significantly alter the company's immediate outlook.

Positives

• Successful capital raise of $1.2 million provides additional working capital for the company's operations.
• The financing structure, including pre-funded warrants, allows for immediate funding while managing beneficial ownership limitations for investors.
• The company has committed to filing a registration statement for the resale of the newly issued shares and warrant shares, which could enhance liquidity for investors in the future.
• The company explicitly states its compliance with Nasdaq listing requirements and its intention to maintain such compliance.

Negatives

• The issuance of warrants introduces potential future dilution for existing shareholders if and when these warrants are exercised.
• The exercise prices of the common stock warrants ($3.50 and $4.00) are above the unit purchase price ($3.00), meaning investors will need the stock price to appreciate to realize value from warrant exercise.

Risks

• Dilution Risk: Future exercise of the common stock purchase warrants will increase the number of outstanding common shares, potentially diluting the ownership percentage of current shareholders.
• Regulatory Compliance Risk: Failure to timely file the required registration statement or maintain compliance with SEC reporting and Nasdaq listing requirements could negatively impact the company and its stock price.
• Market Price Volatility: The value of the common stock and warrants is subject to market fluctuations, which could affect the profitability of the investment for the new investors.
• Resale Restrictions: The newly issued securities are restricted and can only be resold pursuant to an effective registration statement or an available exemption from registration, such as Rule 144.
• Litigation Risk: The company is subject to potential actions by stockholders not affiliated with the new investors if there are material breaches of the agreements or violations of securities laws.

Future Outlook

The company plans to use the net proceeds from this offering for general corporate and working capital purposes, supporting its ongoing operations. It has also committed to filing a registration statement (Form S-1) within 60 calendar days to facilitate the resale of the newly issued shares and warrant shares, indicating an intent to provide liquidity for these investors.

Management Comments

• Greg Lipschitz, Chief Executive Officer, executed the Securities Purchase Agreement and the associated warrant forms on behalf of Firefly Neuroscience, Inc., indicating management's commitment to the financing.

Industry Context

This capital raise is a common financing strategy for growth-stage companies, particularly in the neuroscience or broader biotech sector, to secure essential funding for operations, research and development, or general corporate needs. The unit structure, combining immediate equity with warrants, is a typical approach to attract accredited investors, offering both current participation and potential future upside, while also managing immediate dilution and beneficial ownership limits.

Legal Proceedings

• The company represents that there are no pending or threatened actions, suits, proceedings, or investigations against it that question the validity of the agreement or the right to consummate the transactions, or that might result in material adverse changes to the company's assets, condition, or affairs.
• The company is not a party to or subject to any order, writ, injunction, judgment, or decree of any court or government agency.
• The company is not aware of any basis for such claims or proceedings.

Stakeholder Impact

• Shareholders: Face potential future dilution from the exercise of warrants, but benefit from the company securing additional working capital to support operations and strategic initiatives.
• New Investors: Acquire equity and warrant positions, offering potential for capital appreciation, subject to beneficial ownership limitations and resale restrictions until the registration statement becomes effective.
• Company Operations: The influx of $1.2 million in gross proceeds provides crucial funding for general corporate and working capital needs, supporting ongoing business activities.

Next Steps

• The company is required to file a registration statement on Form S-1 (or equivalent) for the resale of all Shares and Warrant Shares within 60 calendar days of the Closing Date (by August 15, 2025).
• The company must use commercially reasonable efforts to ensure the registration statement is declared effective promptly and maintain its continuous effectiveness.
• The company is committed to maintaining the listing or quotation of its Common Stock on the Nasdaq Capital Market.
• The company will maintain the eligibility of its common stock for electronic transfer through the Depository Trust Company.

Key Dates

Recommendation

Keywords

Firefly Neuroscience, AIFF, Private Placement, Capital Raise, Warrants, Common Stock, SEC Filing, Equity Financing, Accredited Investors, Dilution, Nasdaq Capital Market, Corporate Finance